AMVUTTRA crosses a billion, but growth expectations cool
- Alnylam is the definitive leader in RNA interference, a drug method that turns down harmful genes.
- The main growth engine is AMVUTTRA, which crossed $1 billion in quarterly revenue in Q2 2026.
- Management lowered 2026 net product revenue guidance to $4.7 billion to $5.1 billion as early launch demand normalized.
- A major competitor, eplontersen, failed a Phase 3 study, strengthening Alnylam's position in the market.
- The hard parts include regulatory marketing scrutiny, a margin ceiling near 30%, and relying heavily on a single franchise.
A massive launch meets reality
Alnylam has moved from a promising biotech to a real commercial drug company. The key reason is AMVUTTRA. In Q2 2026, AMVUTTRA crossed $1 billion in revenue for a single quarter, reflecting a run rate over $4 billion. The competitive landscape also shifted in Alnylam's favor when rival drug eplontersen failed its Phase 3 study.
The bull case is built on this commercial strength. Alnylam leads RNAi, has several approved drugs, and secured a new distribution partnership with BeOne for AMVUTTRA in China and Macau. Its Alnylam 2030 plan targets 25% or more total revenue compound annual growth and about a 30% non-GAAP operating margin by 2030.
The bear case centers on the pace of that growth. Management lowered 2026 product revenue guidance in July 2026. The initial wave of pent-up demand from second-line patients exhausted faster than expected. Future growth relies heavily on finding and treating first-line patients.
The stock also carries regulatory and profit questions. Royalty payments on AMVUTTRA and heavy Phase 3 research spending mean profits may not scale as fast as top-line revenue. Two FDA untitled letters about AMVUTTRA promotion and a government price reporting subpoena make the story less clean.
Drug sales first, partner checks second
Alnylam makes money in three ways: selling its own drugs, collecting collaboration revenue from partners, and earning royalties on partner-sold drugs. Its four self-marketed products are AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
The direct drug business is now much larger than the rest. The TTR franchise is the primary driver, with AMVUTTRA alone representing an annual run rate of more than $4 billion as of Q2 2026. This shows how concentrated the business has become around one main therapy.
Partner revenue adds useful funding and geographic reach. Novartis sells Leqvio, Sanofi sells Qfitlia, Roche is partnered on zilebesiran, and BeOne is now the exclusive commercial distributor for AMVUTTRA in Mainland China and Macau. Royalties from Novartis and Sanofi provide high-margin cash flow.
The model breaks if AMVUTTRA loses share or if pricing gets worse. With guidance lowered for 2026, the company must prove it can sustainably find new first-line patients to replace the initial surge of second-line demand.
Approved drugs and big bets
AMVUTTRA
AMVUTTRA treats hATTR amyloidosis with polyneuropathy and ATTR cardiomyopathy. It crossed $1 billion in quarterly revenue in Q2 2026.
ONPATTRO
ONPATTRO treats the polyneuropathy form of hATTR amyloidosis. It is older than AMVUTTRA, and many patients have switched to the newer drug.
GIVLAARI and OXLUMO
GIVLAARI treats acute hepatic porphyria, and OXLUMO treats primary hyperoxaluria type 1. They give Alnylam rare disease revenue outside TTR.
Leqvio and Qfitlia royalties
Leqvio is sold by Novartis, and Qfitlia is sold by Sanofi. These drugs add high-margin royalty revenue without Alnylam running the sales effort.
Nucresiran
Nucresiran is a next-generation TTR program. A Phase 3 cardiomyopathy study expanded its target enrollment to 1,750 patients due to fast pacing.
Zilebesiran
Zilebesiran is an RNAi treatment for hypertension, partnered with Roche. A Phase 3 cardiovascular outcomes trial is expected to start in H2 2025.
ALN-HTT02 and obesity program
ALN-HTT02 is in Phase 1 for Huntington's disease. Alnylam also has a Phase 1 adipose-targeted obesity program underway.
Product sales dominate the mix
This mix reflects the Q2 2026 period, broken into net product revenue, collaboration revenue, and royalty revenue. Product sales dominate entirely.
What could break the story
AMVUTTRA new patient starts stall
High impact · Medium oddsAlnylam lowered 2026 guidance because early second-line pent-up demand normalized. The company now depends on first-line new patient starts to hit its revised $4.7 billion to $5.1 billion target. If first-line adoption is slow, growth will miss expectations.
Margins disappoint investors
Medium impact · Medium oddsManagement has pointed investors to about a 30% non-GAAP operating margin by 2030. That is held down by AMVUTTRA royalty payments and heavy Phase 3 research spending. If investors expect much higher software-like margins, the stock could struggle even while revenue grows.
FDA promotion scrutiny restricts marketing
Medium impact · Medium oddsIn April 2026, the FDA sent Alnylam an untitled letter saying parts of the AMVUTTRA consumer website were false and misleading. That followed a similar September 2025 letter. More action could force changes in marketing and slow patient outreach.
Government price reporting investigation
High impact · Low oddsAlnylam received a subpoena from the U.S. Attorney's Office related to government price reporting for its four commercial products. If violations are found, significant financial penalties and management distraction could follow.
Pipeline clinical trials fail
Medium impact · Medium oddsAlnylam needs follow-on programs to make the 2030 plan work. Nucresiran, zilebesiran, mivelsiran, and the obesity program all carry clinical risk. Failed trials would lower the long-term growth case significantly.
In one breath
What does Alnylam actually do?
Alnylam develops RNAi medicines. RNAi drugs are designed to silence, or turn down, genes that help cause disease.
Why is AMVUTTRA so important to Alnylam?
AMVUTTRA is the main growth engine after its ATTR cardiomyopathy launch. In Q2 2026, AMVUTTRA crossed $1 billion in revenue for a single quarter.
Is Alnylam profitable?
Alnylam reported its first full-year GAAP profitability in 2025. Management targets a 30% non-GAAP operating margin by 2030, but royalties and research spending limit how fast profits scale.
What is the biggest risk for ALNY stock?
The biggest risk is that AMVUTTRA growth slows as early pent-up demand normalizes. Other key risks are FDA scrutiny of promotion, a government price reporting subpoena, and trial failures.
